Related Experiment Video

Updated: Aug 11, 2026

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants
18:01

Paradigms for Pharmacological Characterization of C. elegans Synaptic Transmission Mutants

Published on: August 19, 2008

Albendazole therapy for persistent, solitary cysticercus granulomas in patients with seizures

V Rajshekhar1

  • 1Department of Neurological Sciences, Christian Medical College Hospital, Vellore, India.

Neurology
|June 1, 1993
PubMed

Insights

Albendazole treatment for persistent neurocysticercosis granulomas showed promising results. In some patients, this medication helped resolve or shrink these brain lesions, aiding diagnosis.

Area of Science:

  • Neurology
  • Infectious Diseases
  • Radiology

Background:

  • Neurocysticercosis is a significant cause of seizures worldwide.
  • Cysticercus granulomas are a common manifestation of neurocysticercosis.
  • Persistent granulomas pose a diagnostic and therapeutic challenge.

Purpose of the Study:

  • To evaluate the efficacy of albendazole in treating persistent, solitary small cysticercus granulomas.
  • To assess the impact of albendazole on lesion resolution and size reduction.
  • To determine if albendazole therapy can aid in confirming the diagnosis of cysticercus granuloma.

Main Methods:

  • Eleven patients with persistent (> 3 months) solitary small cysticercus granulomas and seizures were treated.
  • Albendazole was administered at a daily dose of 15 mg/kg body weight for 14 days.
  • Repeat CT examinations were performed 2.5 to 6 weeks post-therapy.

Main Results:

  • Lesion resolution was observed in two out of eleven patients.
  • Significant lesion size reduction (less than 50%) was noted in two additional patients.
  • Albendazole therapy hastened lesion resolution in responders.

Conclusions:

  • Albendazole therapy can be effective in resolving or reducing the size of persistent cysticercus granulomas.
  • Treatment response to albendazole may help confirm the diagnosis of cysticercus granuloma.
  • Further studies are warranted to establish optimal treatment protocols.

More Related Videos

Transient Transduction of the Strobilated Forms of Echinococcus granulosus13:25

Transient Transduction of the Strobilated Forms of Echinococcus granulosus

Published on: September 16, 2022

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus09:04

Isolation And Dendritic Cell-Uptake of Small Extracellular Vesicles from Echinococcus granulosus

Published on: March 28, 2025

Related Concept Videos

Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic sinusitis...
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early years,...
Cryptococcal Meningitis01:27

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...